5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Non-infectious O
pneumonitis O
: O
Monitor O
for O
clinical O
symptoms O
or O
radiological O
changes O
; O
fatal O
cases O
have O
occurred O
. O

Manage O
by O
dose O
reduction O
or O
discontinuation O
until O
symptoms O
resolve O
, O
and O
consider O
use O
of O
corticosteroids O
. O

( O
5.1 O
) O
* O
Infections O
: O
Increased O
risk O
of O
infections O
, O
some O
fatal O
. O

Monitor O
for O
signs O
and O
symptoms O
, O
and O
treat O
promptly O
. O

( O
5.2 O
) O
* O
Angioedema O
: O
Patients O
taking O
concomitant O
ACE O
inhibitor O
therapy O
may O
be O
at O
increased O
risk O
for O
angioedema O
. O

( O
5.3 O
) O
* O
Stomatitis O
: O
Stomatitis O
, O
including O
mouth O
ulcers O
and O
oral O
mucositis O
, O
occurs O
in O
most O
patients O
treated O
with O
AFINITOR O
. O

Initiation O
of O
topical O
treatment O
with O
dexamethasone O
mouthwash O
when O
starting O
AFINITOR O
reduces O
the O
incidence O
and O
severity O
of O
stomatitis O
. O

( O
5.4 O
, O
6.1 O
) O
* O
Renal O
failure O
: O
Cases O
of O
renal O
failure O
( O
including O
acute O
renal O
failure O
) O
, O
some O
with O
a O
fatal O
outcome O
, O
have O
been O
observed O
. O

( O
5.5 O
) O
* O
Impaired O
wound O
healing O
: O
Increased O
risk O
of O
wound-related O
complications O
. O

Monitor O
signs O
and O
symptoms O
. O

Exercise O
caution O
in O
the O
peri-surgical O
period O
. O

( O
5.6 O
) O
* O
Laboratory O
test O
alterations O
: O
Elevations O
of O
serum O
creatinine O
, O
urinary O
protein O
, O
blood O
glucose O
, O
and O
lipids O
may O
occur O
. O

Decreases O
in O
hemoglobin O
, O
neutrophils O
, O
and O
platelets O
may O
also O
occur O
. O

Monitor O
renal O
function O
, O
blood O
glucose O
, O
lipids O
, O
and O
hematologic O
parameters O
prior O
to O
treatment O
and O
periodically O
thereafter O
. O

( O
5.8 O
) O
* O
Vaccinations O
: O
Avoid O
live O
vaccines O
and O
close O
contact O
with O
those O
who O
have O
received O
live O
vaccines O
. O

( O
5.11 O
) O
* O
Embryo-Fetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
patients O
of O
reproductive O
potential O
of O
the O
potential O
risk O
to O
a O
fetus O
and O
to O
use O
effective O
contraception O
. O

( O
5.12 O
, O
8.1 O
, O
8.3 O
) O
5.1 O
Non-infectious O
Pneumonitis O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
is O
a O
class O
effect O
of O
rapamycin O
derivatives O
, O
including O
AFINITOR O
. O

Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
was O
reported O
in O
up O
to O
19 O
% O
of O
patients O
treated O
with O
AFINITOR O
in O
clinical O
trials O
, O
some O
cases O
reported O
with O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
( O
including O
pulmonary B-OSE_Labeled_AE
arterial I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
) O
as O
a O
secondary O
event O
. O

The O
incidence O
of O
Common O
Terminology O
Criteria O
( O
CTC O
) O
Grade O
3 O
and O
4 O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
was O
up O
to O
4.0 O
% O
and O
up O
to O
0.2 O
% O
, O
respectively O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Fatal B-NonOSE_AE
outcomes O
have O
been O
observed O
. O

Consider O
a O
diagnosis O
of O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
in O
patients O
presenting O
with O
non-specific O
respiratory O
signs O
and O
symptoms O
such O
as O
hypoxia B-NonOSE_AE
, O
pleural B-NonOSE_AE
effusion I-NonOSE_AE
, O
cough B-NonOSE_AE
, O
or O
dyspnea B-NonOSE_AE
, O
and O
in O
whom O
infectious B-Not_AE_Candidate
, O
neoplastic B-Not_AE_Candidate
, O
and O
other O
causes O
have O
been O
excluded O
by O
means O
of O
appropriate O
investigations O
. O

Opportunistic B-NonOSE_AE
infections I-NonOSE_AE
such O
as O
pneumocystis B-NonOSE_AE
jiroveci I-NonOSE_AE
pneumonia I-NonOSE_AE
( I-NonOSE_AE
PJP I-NonOSE_AE
) O
should O
be O
considered O
in O
the O
differential O
diagnosis O
. O

Advise O
patients O
to O
report O
promptly O
any O
new O
or O
worsening B-NonOSE_AE
respiratory I-NonOSE_AE
symptoms I-NonOSE_AE
. O

Patients O
who O
develop O
radiological O
changes O
suggestive O
of O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
and O
have O
few O
or O
no O
symptoms O
may O
continue O
AFINITOR O
therapy O
without O
dose O
alteration O
. O

Imaging O
appears O
to O
overestimate O
the O
incidence O
of O
clinical O
pneumonitis B-NonOSE_AE
. O

If O
symptoms O
are O
moderate O
, O
consider O
interrupting O
therapy O
until O
symptoms O
improve O
. O

The O
use O
of O
corticosteroids O
may O
be O
indicated O
. O

AFINITOR O
may O
be O
reintroduced O
at O
a O
daily O
dose O
approximately O
50 O
% O
lower O
than O
the O
dose O
previously O
administered O
[ O
see O
Table O
1 O
in O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

For O
cases O
of O
Grade O
3 O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
, O
interrupt O
AFINITOR O
until O
resolution O
to O
less O
than O
or O
equal O
to O
Grade O
1 O
. O

AFINITOR O
may O
be O
re-introduced O
at O
a O
daily O
dose O
approximately O
50 O
% O
lower O
than O
the O
dose O
previously O
administered O
depending O
on O
the O
individual O
clinical O
circumstances O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

If O
toxicity O
recurs O
at O
Grade O
3 O
, O
consider O
discontinuation O
of O
AFINITOR O
. O

For O
cases O
of O
Grade O
4 O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
, O
discontinue O
AFINITOR O
. O

Corticosteroids O
may O
be O
indicated O
until O
clinical O
symptoms O
resolve O
. O

For O
patients O
who O
require O
use O
of O
corticosteroids O
for O
treatment O
of O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
, O
prophylaxis O
for O
PJP B-NonOSE_AE
may O
be O
considered O
. O

The O
development O
of O
pneumonitis B-OSE_Labeled_AE
has O
been O
reported O
even O
at O
a O
reduced O
dose O
. O

5.2 O
Infections O
AFINITOR O
has O
immunosuppressive B-OSE_Labeled_AE
properties O
and O
may O
predispose O
patients O
to O
bacterial B-OSE_Labeled_AE
, O
fungal O
, O
viral O
, O
or O
protozoal O
infections I-OSE_Labeled_AE
, O
including O
infections B-OSE_Labeled_AE
with I-OSE_Labeled_AE
opportunistic I-OSE_Labeled_AE
pathogens I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Localized B-OSE_Labeled_AE
and O
systemic O
infections I-OSE_Labeled_AE
, O
including O
pneumonia B-OSE_Labeled_AE
, O
mycobacterial B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
other O
bacterial B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
such O
as O
aspergillosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
or O
pneumocystis B-OSE_Labeled_AE
jiroveci I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PJP I-OSE_Labeled_AE
) O
and O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
including O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
have O
occurred O
in O
patients O
taking O
AFINITOR O
. O

Some O
of O
these O
infections B-NonOSE_AE
have O
been O
severe O
( O
e.g. O
, O
leading O
to O
sepsis B-NonOSE_AE
, O
respiratory B-NonOSE_AE
or O
hepatic O
failure I-NonOSE_AE
) O
or O
fatal B-NonOSE_AE
. O

Physicians O
and O
patients O
should O
be O
aware O
of O
the O
increased O
risk O
of O
infection B-NonOSE_AE
with O
AFINITOR O
. O

Complete O
treatment O
of O
pre-existing O
invasive B-Not_AE_Candidate
fungal I-Not_AE_Candidate
infections I-Not_AE_Candidate
prior O
to O
starting O
treatment O
with O
AFINITOR O
. O

While O
taking O
AFINITOR O
, O
be O
vigilant O
for O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
; O
if O
a O
diagnosis O
of O
an O
infection B-NonOSE_AE
is O
made O
, O
institute O
appropriate O
treatment O
promptly O
and O
consider O
interruption O
or O
discontinuation O
of O
AFINITOR O
. O

If O
a O
diagnosis O
of O
invasive B-NonOSE_AE
systemic I-NonOSE_AE
fungal I-NonOSE_AE
infection I-NonOSE_AE
is O
made O
, O
discontinue O
AFINITOR O
and O
treat O
with O
appropriate O
antifungal O
therapy O
. O

Pneumocystis B-OSE_Labeled_AE
jiroveci I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
, O
some O
with O
a O
fatal B-NonOSE_AE
outcome O
, O
has O
been O
reported O
in O
patients O
who O
received O
everolimus O
. O

This O
may O
be O
associated O
with O
concomitant O
use O
of O
corticosteroids O
or O
other O
immunosuppressive B-NonOSE_AE
agents O
. O

Prophylaxis O
for O
PJP B-NonOSE_AE
should O
be O
considered O
when O
concomitant O
use O
of O
corticosteroids O
or O
other O
immunosuppressive B-NonOSE_AE
agents O
are O
required O
. O

5.3 O
Angioedema O
with O
Concomitant O
Use O
of O
Angiotensin-Converting O
Enzyme O
( O
ACE O
) O
Inhibitors O
Patients O
taking O
concomitant O
ACE O
inhibitor O
therapy O
may O
be O
at O
increased O
risk O
for O
angioedema B-NonOSE_AE
( O
e.g. O
, O
swelling B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
airways O
or O
tongue I-NonOSE_AE
, O
with O
or O
without O
respiratory B-NonOSE_AE
impairment I-NonOSE_AE
) O
. O

In O
a O
pooled O
analysis O
of O
randomized O
double-blind O
oncology O
clinical O
trials O
, O
the O
incidence O
of O
angioedema B-NonOSE_AE
in O
patients O
taking O
everolimus O
with O
an O
ACE O
inhibitor O
was O
6.8 O
% O
compared O
to O
1.3 O
% O
in O
the O
control O
arm O
with O
an O
ACE O
inhibitor O
. O

5.4 O
Stomatitis O
Stomatitis B-OSE_Labeled_AE
, O
including O
mouth B-OSE_Labeled_AE
ulcers I-OSE_Labeled_AE
and O
oral B-OSE_Labeled_AE
mucositis I-OSE_Labeled_AE
, O
has O
occurred O
in O
patients O
treated O
with O
AFINITOR O
at O
an O
incidence O
ranging O
from O
44 O
% O
-78 O
% O
across O
the O
clinical O
trial O
experience O
. O

Grade O
3 O
or O
4 O
stomatitis B-OSE_Labeled_AE
was O
reported O
in O
4 O
% O
-9 O
% O
of O
patients O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Stomatitis B-OSE_Labeled_AE
most O
often O
occurs O
within O
the O
first O
8 O
weeks O
of O
treatment O
. O

When O
starting O
AFINITOR O
, O
initiating O
dexamethasone O
alcohol-free O
oral O
solution O
as O
a O
swish O
and O
spit O
mouthwash O
reduces O
the O
incidence O
and O
severity O
of O
stomatitis B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

If O
stomatitis B-NonOSE_AE
does O
occur O
, O
mouthwashes O
and/or O
other O
topical O
treatments O
are O
recommended O
, O
but O
alcohol- O
, O
hydrogen O
peroxide- O
, O
iodine- O
, O
or O
thyme- O
containing O
products O
should O
be O
avoided O
as O
they O
may O
exacerbate O
the O
condition O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Antifungal O
agents O
should O
not O
be O
used O
unless O
fungal B-NonOSE_AE
infection I-NonOSE_AE
has O
been O
diagnosed O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.5 O
Renal O
Failure O
Cases O
of O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
including O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
) O
, O
some O
with O
a O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
observed O
in O
patients O
treated O
with O
AFINITOR O
[ O
see O
Laboratory O
Tests O
and O
Monitoring O
( O
5.8 O
) O
] O
. O

5.6 O
Impaired O
Wound O
Healing O
Everolimus O
delays B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
and O
increases O
the O
occurrence O
of O
wound B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
like O
wound B-OSE_Labeled_AE
dehiscence I-OSE_Labeled_AE
, O
wound B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
incisional B-OSE_Labeled_AE
hernia I-OSE_Labeled_AE
, O
lymphocele B-OSE_Labeled_AE
, O
and O
seroma B-OSE_Labeled_AE
. O

These O
wound B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
complications I-NonOSE_AE
may O
require O
surgical O
intervention O
. O

Exercise O
caution O
with O
the O
use O
of O
AFINITOR O
in O
the O
peri-surgical O
period O
. O

5.7 O
Geriatric O
Patients O
In O
the O
randomized O
advanced O
hormone B-Not_AE_Candidate
receptor I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
, I-Not_AE_Candidate
HER I-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
negative I-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
study O
( O
BOLERO-2 O
) O
, O
the O
incidence O
of O
deaths B-NonOSE_AE
due O
to O
any O
cause O
within O
28 O
days O
of O
the O
last O
AFINITOR O
dose O
was O
6 O
% O
in O
patients O
> O
= O
65 O
years O
of O
age O
compared O
to O
2 O
% O
in O
patients O
< O
65 O
years O
of O
age O
. O

Adverse O
reactions O
leading O
to O
permanent O
treatment O
discontinuation O
occurred O
in O
33 O
% O
of O
patients O
> O
= O
65 O
years O
of O
age O
compared O
to O
17 O
% O
in O
patients O
< O
65 O
years O
of O
age O
. O

Careful O
monitoring O
and O
appropriate O
dose O
adjustments O
for O
adverse O
reactions O
are O
recommended O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

5.8 O
Laboratory O
Tests O
and O
Monitoring O
Renal O
Function O
Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
and O
proteinuria B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
AFINITOR O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Monitoring O
of O
renal O
function O
, O
including O
measurement O
of O
blood O
urea O
nitrogen O
( O
BUN O
) O
, O
urinary O
protein O
, O
or O
serum O
creatinine O
, O
is O
recommended O
prior O
to O
the O
start O
of O
AFINITOR O
therapy O
and O
periodically O
thereafter O
. O

Renal O
function O
of O
patients O
should O
be O
monitored O
particularly O
where O
patients O
have O
additional O
risk O
factors O
that O
may O
further O
impair B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

Blood O
Glucose O
and O
Lipids O
Hyperglycemia B-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
and O
hypertriglyceridemia B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
AFINITOR O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Monitoring O
of O
fasting O
serum O
glucose O
and O
lipid O
profile O
is O
recommended O
prior O
to O
the O
start O
of O
AFINITOR O
therapy O
and O
periodically O
thereafter O
as O
well O
as O
management O
with O
appropriate O
medical O
therapy O
. O

More O
frequent O
monitoring O
is O
recommended O
when O
AFINITOR O
is O
co-administered O
with O
other O
drugs O
that O
may O
induce O
hyperglycemia B-NonOSE_AE
. O

When O
possible O
, O
optimal O
glucose O
and O
lipid O
control O
should O
be O
achieved O
before O
starting O
a O
patient O
on O
AFINITOR O
. O

Hematologic O
Parameters O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
lymphocytes O
, O
neutrophils O
, O
and O
platelets O
have O
been O
reported O
in O
patients O
taking O
AFINITOR O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Monitoring O
of O
complete O
blood O
count O
is O
recommended O
prior O
to O
the O
start O
of O
AFINITOR O
therapy O
and O
periodically O
thereafter O
. O

5.9 O
Drug-Drug O
Interactions O
Due O
to O
significant O
increases O
in O
exposure O
of O
everolimus O
, O
co-administration O
with O
strong O
CYP3A4/PgP O
inhibitors O
should O
be O
avoided O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
, O
2.5 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

A O
reduction O
of O
the O
AFINITOR O
dose O
is O
recommended O
when O
co-administered O
with O
a O
moderate O
CYP3A4/PgP O
inhibitor O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
, O
2.5 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

An O
increase O
in O
the O
AFINITOR O
dose O
is O
recommended O
when O
co-administered O
with O
a O
strong O
CYP3A4/PgP O
inducer O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
, O
2.5 O
) O
and O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.10 O
Hepatic O
Impairment O
Exposure O
to O
everolimus O
was O
increased O
in O
patients O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

For O
advanced B-Not_AE_Candidate
HR I-Not_AE_Candidate
+ I-Not_AE_Candidate
BC I-Not_AE_Candidate
, O
advanced B-Not_AE_Candidate
NET I-Not_AE_Candidate
, O
advanced B-Not_AE_Candidate
RCC I-Not_AE_Candidate
, O
and O
renal B-Not_AE_Candidate
angiomyolipoma I-Not_AE_Candidate
with I-Not_AE_Candidate
TSC I-Not_AE_Candidate
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
Child-Pugh O
class O
C O
) O
, O
AFINITOR O
may O
be O
used O
at O
a O
reduced O
dose O
if O
the O
desired O
benefit O
outweighs O
the O
risk O
. O

For O
patients O
with O
mild O
( O
Child-Pugh O
class O
A O
) O
or O
moderate O
( O
Child-Pugh O
class O
B O
) O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
a O
dose O
reduction O
is O
recommended O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

For O
patients O
with O
SEGA B-Not_AE_Candidate
and O
mild O
or O
moderate O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
adjust O
the O
dose O
of O
AFINITOR O
Tablets O
or O
AFINITOR O
DISPERZ O
based O
on O
therapeutic O
drug O
monitoring O
. O

For O
patients O
with O
SEGA B-Not_AE_Candidate
and O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
reduce O
the O
starting O
dose O
of O
AFINITOR O
Tablets O
or O
AFINITOR O
DISPERZ O
by O
approximately O
50 O
% O
and O
adjust O
subsequent O
doses O
based O
on O
therapeutic O
drug O
monitoring O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
, O
2.5 O
) O
] O
. O

5.11 O
Vaccinations O
During O
AFINITOR O
treatment O
, O
avoid O
the O
use O
of O
live O
vaccines O
and O
avoid O
close O
contact O
with O
individuals O
who O
have O
received O
live O
vaccines O
( O
e.g. O
, O
intranasal B-NonOSE_AE
influenza I-NonOSE_AE
, O
measles O
, O
mumps O
, O
rubella O
, O
oral O
polio O
, O
BCG O
, O
yellow O
fever O
, O
varicella O
, O
and O
TY21a O
typhoid O
vaccines I-NonOSE_AE
) O
. O

For O
pediatric O
patients O
with O
SEGA B-Not_AE_Candidate
that O
do O
not O
require O
immediate O
treatment O
, O
complete O
the O
recommended O
childhood O
series O
of O
live O
virus O
vaccinations O
according O
to O
American O
Council O
on O
Immunization O
Practices O
( O
ACIP O
) O
guidelines O
prior O
to O
the O
start O
of O
therapy O
. O

An O
accelerated O
vaccination O
schedule O
may O
be O
appropriate O
. O

5.12 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
animal O
studies O
and O
the O
mechanism O
of O
action O
[ O
see O
Clinical O
Pharmacology O
( O
12.1 O
) O
] O
, O
AFINITOR O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

In O
animal O
studies O
, O
everolimus O
caused O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
toxicities I-NonOSE_AE
in O
rats O
when O
administered O
during O
the O
period O
of O
organogenesis O
at O
maternal O
exposures O
that O
were O
lower O
than O
human O
exposures O
at O
the O
clinical O
dose O
of O
10 O
mg O
daily O
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-NonOSE_AE
to I-NonOSE_AE
a I-NonOSE_AE
fetus I-NonOSE_AE
. O

Advise O
female O
patients O
of O
reproductive O
potential O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
and O
to O
use O
effective O
contraception O
during O
treatment O
with O
AFINITOR O
and O
for O
8 O
weeks O
after O
the O
last O
dose O
. O

Advise O
male O
patients O
with O
female O
partners O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
with O
AFINITOR O
and O
for O
4 O
weeks O
after O
the O
last O
dose O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

